evoke trial semaglutide design of evoke/evoke+. *Participants can receive existing or Disappointing GLP-1 Results in Alzheimer's

Nakamura T, Conrad M

'Game changers' with future cost savings Most private insurers dont cover GLP-1s for weight loss, which can make the drugs unaffordable for those paying out of pocket

Liraglutide has recently been reported to induce gut microbial structural changes in DIO mice, dominated by changes in the distribution of Proteobacteria and Verrucomicrobia phylotypes without affecting the abundance of Firmicutes 69

Based on the current progression of PD treatment and prevention, diet is receiving increasing attention from many researchers and is thought to be another important measure for the treatment and prevention of PD besides pharmacy and surgery (7)